Antibody Profile Comparison against MSP1 Antigens of Multiple Plasmodium Species in Human Serum Samples from Two Different Brazilian Populations Using a Multiplex Serological Assay

Carregando...
Imagem de Miniatura
Citações na Scopus
2
Tipo de produção
article
Data de publicação
2021
Título da Revista
ISSN da Revista
Título do Volume
Editora
MDPI
Autores
FERNANDEZ-BECERRA, Carmen
WUNDERLICH, Gerhard
HIYANE, Meire Ioshie
Citação
PATHOGENS, v.10, n.9, article ID 1138, 13p, 2021
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Plasmodium malariae has a wide geographic distribution, but mainly at very low parasitemias and in co-infections, leading to an underestimated prevalence of this species. Studies for the detection of antibodies against Plasmodium recombinant proteins are increasingly used to map geographical distributions, seroprevalence and transmission intensities of malaria infection. However, no seroepidemiological survey using recombinant P. malariae proteins has been conducted in Brazil. This work evaluated the antibody response in serum samples of individuals from endemic regions of Brazil (the Amazon region and Atlantic Forest) against five recombinant proteins of P. malariae merozoite surface protein 1 (MSP1), and the MSP1 C-terminal portions of P. vivax and P. falciparum, in a multiplex assay. The positivity was 69.5% of samples recognizing at least one MSP1 recombinant protein. The mean of the Reactivity Index for the C-terminal portion of the P. falciparum was significantly higher compared to the other recombinant proteins, followed by the C-terminal of P. vivax and the N-terminal of P. malariae. Among the recombinant P. malariae proteins, the N-terminal of P. malariae showed the highest Reactivity Index alone. This study validates the use of the multiplex assay to measure naturally acquired IgG antibodies against Plasmodium MSP1 proteins and demonstrate that these proteins are important tools for seroepidemiological surveys and could be used in malaria surveillance.
Palavras-chave
malaria, Plasmodium malariae, MSP1, serology, Brazil, multiplex bead assay
Referências
  1. [Anonymous], 2018, WORLD MAL REP 2018
  2. Aschar M, 2020, REV INST MED TROP SP, V62, DOI [10.1590/S1678-9946202062100, 10.1590/s1678-9946202062100]
  3. Assefa A, 2019, MALARIA J, V18, DOI 10.1186/s12936-019-2874-z
  4. Bousema T, 2014, NAT REV MICROBIOL, V12, P833, DOI 10.1038/nrmicro3364
  5. Buery JC, 2021, MICROORGANISMS, V9, DOI 10.3390/microorganisms9010132
  6. Carlos B.C., 2019, PATHOG GLOB HEALTH, V113, P1, DOI [10.1080/20477724.2019.1581463, DOI 10.1080/20477724.2019.1581463]
  7. Cassiano GC, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1350-2
  8. Cheaveau J, 2019, EXPERT REV ANTI-INFE, V17, P997, DOI 10.1080/14787210.2019.1693259
  9. Cohen JM, 2017, MALARIA J, V16, DOI 10.1186/s12936-017-2106-3
  10. Collins WE, 2007, CLIN MICROBIOL REV, V20, P579, DOI 10.1128/CMR.00027-07
  11. Costa EMF, 2020, ACTA TROP, V209, DOI 10.1016/j.actatropica.2020.105537
  12. Cowan GJM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087198
  13. Curado I, 1997, MEM I OSWALDO CRUZ, V92, P235, DOI 10.1590/S0074-02761997000200017
  14. Curado I, 2006, ACTA TROP, V100, P54, DOI 10.1016/j.actatropica.2006.09.010
  15. de Castro Duarte A.M.R., 2021, CURR RES PARASITOL V, V1, DOI [10.1016/j.crpvbd.2021.100032, DOI 10.1016/J.CRPVBD.2021.100032]
  16. Elizardez YB, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0219629
  17. Feleke SM, 2019, MALARIA J, V18, DOI 10.1186/s12936-019-2927-3
  18. Fernandez-Becerra C, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-29
  19. Garnham P.C.C., 1966, MALARIA PARASITES OT
  20. Gilles HM, 1993, BRUCE CHWATTS ESSENT
  21. Grande R, 2019, MALARIA J, V18, DOI 10.1186/s12936-019-2806-y
  22. Hawadak J, 2021, PARASITE VECTOR, V14, DOI 10.1186/s13071-021-04797-0
  23. Holder AA, 2009, PARASITOLOGY, V136, P1445, DOI 10.1017/S0031182009990515
  24. Labadie-Bracho MY, 2020, MALARIA J, V19, DOI 10.1186/s12936-020-03434-y
  25. Marsh K, 2006, PARASITE IMMUNOL, V28, P51, DOI 10.1111/j.1365-3024.2006.00808.x
  26. McCaffery JN, 2021, MALARIA J, V20, DOI 10.1186/s12936-021-03626-0
  27. Medeiros MM, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-608
  28. Miguel RB, 2019, REV SOC BRAS MED TRO, V52, DOI 10.1590/0037-8682-0537-2018
  29. Monteiro EF, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9070525
  30. Muerhoff AS, 2010, CLIN VACCINE IMMUNOL, V17, P1631, DOI 10.1128/CVI.00196-10
  31. Multini LC, 2019, TRENDS PARASITOL, V35, P383, DOI 10.1016/j.pt.2019.03.009
  32. Nogueira PA, 2006, INFECT IMMUN, V74, P2726, DOI 10.1128/IAI.74.5.2726-2733.2006
  33. Oliveira-Ferreira J, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-115
  34. Oriero EC, 2020, AM J TROP MED HYG, V103, P2208, DOI 10.4269/ajtmh.20-0593
  35. Oriero EC, 2021, CRIT REV MICROBIOL, V47, P44, DOI 10.1080/1040841X.2020.1838440
  36. Pires CV, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207244
  37. Plucinski MM, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006278
  38. Pratt-Riccio LR, 2017, AM J TROP MED HYG, V97, P1581, DOI 10.4269/ajtmh.17-0359
  39. Priest JW, 2018, MALARIA J, V17, DOI 10.1186/s12936-018-2566-0
  40. Punnath Kishore, 2020, J Parasit Dis, P1, DOI 10.1007/s12639-020-01288-4
  41. Scopel KKG, 2004, ACTA TROP, V90, P61, DOI 10.1016/j.actatropica.2003.11.002
  42. Silva-Nunes Mônica da, 2006, Cad. Saúde Pública, V22, P1325, DOI 10.1590/S0102-311X2006000600021
  43. Steinhardt LC, 2021, J INFECT DIS, V223, P995, DOI 10.1093/infdis/jiaa476
  44. Storti-Melo LM, 2011, AM J TROP MED HYG, V84, P58, DOI 10.4269/ajtmh.2011.10-0044
  45. Vinetz JM, 1998, NEW ENGL J MED, V338, P367, DOI 10.1056/NEJM199802053380605
  46. Wipasa J, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000770
  47. Yman V, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007414
  48. Yuen D, 2007, VACCINE, V25, P490, DOI 10.1016/j.vaccine.2006.07.053